In the news release, Hollister Biosciences Inc. Provides Update on Q4 2020 Performance Including CDN $14.93 Million in Revenue With an Estimated CDN $5.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019, issued 07-Jan-2021 by Hollister Biosciences Inc. over CNW, we are advised by the company that the title should read “CDN $2.53 Million in EBITDA ” rather than “CDN $5.53 Million in EBITDA” as … In the news release, Hollister Biosciences Inc. Provides Update on Q4 2020 Performance Including CDN $14.93 Million in Revenue With an Estimated CDN $5.53 Million in EBITDA a YoY Revenue Increase of 3215% from Q4 2019, issued 07-Jan-2021 by Hollister Biosciences Inc. over CNW, we are advised by the company that the title should read “CDN $2.53 Million in EBITDA ” rather than “CDN $5.53 Million in EBITDA” as originally issued inadvertently. The complete, corrected release follows:
Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the
Company ,
Hollister Cannabis Co. or
Hollister ) a diversified cannabis branding company with products in over 280 dispensaries throughout California, and over 90 dispensaries throughout Arizona, is pleased to provide an update on its Q4, 2020 performance.
Q4 2020 Update
st, 2020 and ending December 31
st, 2020, Hollister reports that it generated record quarterly revenue of CDN$14.93 million and CDN$2.53 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products. The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.
triple-digit returns in the last year
Optimism is brewing as governments grant research approvals for the study of psychedelics on mental health
By some estimates, the psychedelic drugs market is projected to see compound annual growth (CAGR) of
16.3% to reach
Psyched About Psychedelics
Psychedelic stocks are trading like biotechnology companies these days. The prospect of promising research has pushed valuations upwards. And like biotech companies, they often report no revenues and are a volatile bunch.
Awareness around mental health disorders is increasing, as are the number of people who suffer from them a figure exacerbated by the pandemic. Although these factors are grim, they are actually catalysts for psychedelic stocks.
Further Research into Psilocybin Opens New Doors for Treatment
FinancialBuzz.com News Commentary
Share this article
Share this article
NEW YORK, Jan. 7, 2021 /PRNewswire/ Among the popular fields of study for biotech companies in recent years are gene editing, tissue engineering and regeneration, nanobiotechnology and others. In addition, new segments under the biotech umbrella are constantly being developed. For example, the medical cannabis segment has rapidly emerged in recent years, and the continuously growing acceptance of psychedelic drugs is further evidence. The perceptions about psychedelics and their possible uses have also started to shift from a potentially dangerous party drug to an approachable medicinal product. For example, earlier in 2019, the U.S. Food and Drug Administration (FDA) approved Spravato (esketamine) a nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines b
Share this article
Share this article
Company ,
Hollister Cannabis Co. or
Hollister ) a diversified cannabis branding company with products in over 280 dispensaries throughout California, and over 80 dispensaries throughout Arizona, is pleased to announce the launch of its 2nd fulfillment depot for its direct-to-consumer cannabis delivery platform, Dreamy Delivery (
Dreamy or the
Platform ).
The Company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California, to ensure a seamless customer experience in early Q4 of 2020. The Company has expanded the Platform, with Dreamy now successfully delivering to legal cannabis consumers in the San Francisco Bay Area of Northern California and now Sacramento, California. The Company hopes to launch Dreamy in the Central Coast of California by early Q1 of 2021 with the ultimate goal of delivering Cannabis statewide.